SUNITINIB (sun-i-ti'nib)
Sutent Classifications: antineoplastic agent; growth factor receptor inhibitor; tyrosine kinase inhibitor; Therapeutic:antineoplastic; growth factor receptor inhibitor; tyrosine kinase inhibitor Prototype: Gefitinib Pregnancy Category: D
|
Availability
12.5 mg, 25 mg, 50 mg capsules
Action
An antineoplastic agent that is a selective inhibitor of receptor tyrosine kinases (RTKs) in solid tumors. Carcinogenic
activity within these tumors is a result of tumor angiogenesis and proliferation.
Therapeutic Effect
Sunitinib causes tumor regression and decreased tumor growth.
Uses
Treatment of advanced renal cell cancer; treatment of gastrointestinal stromal tumors (GIST) after disease progression on
or intolerance to imatinib.
Contraindications
Hypersensitivity to sunitinib; uncontrolled hypertension, acute MI; fever, abnormal bleeding, sore throat; children, pregnancy
(category D), lactation.
Cautious Use
Cardiac disease, CHF, history of hypertension, history of MI; CVA; females of childbearing age.
Route & Dosage
Advanced Renal Cell Cancer Adult: PO 50 mg/d for 4 wk, followed by 2 wk off treatment; repeat 6-wk cycle as needed.
Dosage Adjustments with Concurrent Hepatic CYP3A4 Modifiers CYP3A4 Inducers: increase to maximum of 87.5 mg/d CYP3A4 Inhibitors: decrease to minimum of 37.5 mg/d
|
Administration
Oral
- Note that this drug is given on a 6-wk cycle: 4 wk on therapy and 2 wk off.
- Incremental dosage changes of 12.5 mg are recommended.
- Store at 15°30° C (59°86° F).
Adverse Effects (≥1%)
Body as a Whole: Alopecia, asthenia, dizziness, fatigue, fever, hair color change,
headache, peripheral edema. CV: Hypertension, myocardial ischemia. GI: Abdominal pain, altered taste, anorexia, constipation, diarrhea, dyspepsia, flatulence, glossodynia, nausea, mucositis,
stomatitis, vomiting. Hematologic: Anemia, bleeding, neutropenia, lymphopenia, thrombocytopenia. Metabolic: Dehydration, elevated hepatic enzymes (AST/ALT, alkaline phosphatase, pancreatic enzymes, amylasemia, lipasemia), hypothyroidism,
hyperbilirubinemia. Musculoskeletal: Arthralgia, back pain, myalgia/limb pain. Respiratory: Cough, dyspnea. Skin: Dry skin, hand-foot syndrome, rash, skin discoloration.
Interactions
Drug: Coadministration of CYP3A4 inducers (e.g.,
carbamazepine, dexamethasone, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine) may decrease
plasma levels of sunitinib. Coadministration of CYP3A4 inhibitors (e.g.,
atazanavir, clarithromycin, erythromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir,
telithromycin, voriconazole) may increase
plasma levels of sunitinib.
Food: Grapefruit and
grapefruit juice may increase the
plasma levels of sunitinib.
Herbal: St. John's wort may decrease the
plasma levels of sunitinib.
Pharmacokinetics
Peak: 612 h.
Distribution: 9598% protein bound.
Metabolism: Extensive
hepatic metabolism.
Elimination: Primarily fecal elimination (61%) with minor
renal elimination.
Half-Life: 4060 h.
Nursing Implications
Assessment & Drug Effects
- Monitor for and report S&S of bleeding (e.g., GI, GU, gingival, etc.).
- Monitor BP regularly and assess regularly for S&S of congestive heart failure. Withhold drug and notify physician if severe
hypertension or signs of heart failure develop.
- Lab tests: At the beginning of each treatment cycle, CBC with differential and platelet count; periodic serum electrolytes;
thyroid function tests with symptoms suggestive of hypothyroidism.
Patient & Family Education
- Follow directions for taking the drug (see Administration).
- Do not use any prescription or nonprescription drugs without consulting a physician.
- Skin discoloration (yellow color) and/or loss of skin and hair pigmentation may occur with this drug.
- Report any of the following to a health care provider: painful redness of palms and soles of feet; severe abdominal pain,
vomiting, and diarrhea; signs of bleeding; chest pain or discomfort; shortness of breath; swelling of feet, legs, or hands;
rapid weight gain.
- Women of childbearing age are advised not be become pregnant while taking sunitinib.